![Low adherence to treatment is a weak link in the problems of ulcerative colitis - Parfenov - Terapevticheskii arkhiv Low adherence to treatment is a weak link in the problems of ulcerative colitis - Parfenov - Terapevticheskii arkhiv](https://ter-arkhiv.ru/public/journals/80/cover_issue_4908_en_US.jpg)
Low adherence to treatment is a weak link in the problems of ulcerative colitis - Parfenov - Terapevticheskii arkhiv
![Constipation in ulcerative colitis: pathophysiology and practical management | Frontline Gastroenterology Constipation in ulcerative colitis: pathophysiology and practical management | Frontline Gastroenterology](https://fg.bmj.com/sites/default/files/highwire/flgastro/12/6.cover-source.jpg)
Constipation in ulcerative colitis: pathophysiology and practical management | Frontline Gastroenterology
Steroid Resistance/Dependence Might Be an Alarming Feature for Cytomegalovirus Infection Among Ulcerative Colitis Patients With
Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowe
![Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease - ScienceDirect Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S177322472100232X-ga1.jpg)
Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease - ScienceDirect
Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe
![Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology](https://bmjopengastro.bmj.com/content/bmjgast/7/1/e000456/F1.large.jpg)
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology
![PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis](https://i1.rgstatic.net/publication/340004460_Lymphocyte_Activation_Gene_LAG-3_Is_Associated_With_Mucosal_Inflammation_and_Disease_Activity_in_Ulcerative_Colitis/links/5e78ba49299bf1892c0235fe/largepreview.png)
PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
![Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study - Pugliese - 2022 - Alimentary Pharmacology & Therapeutics - Wiley Online Library Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study - Pugliese - 2022 - Alimentary Pharmacology & Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c080de5c-6f74-48b3-9608-bd6feb7e6dce/apt16923-toc-0001-m.jpg?trick=1656871978222)
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study - Pugliese - 2022 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
![2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 11 of 11 - Tom Wade MD 2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 11 of 11 - Tom Wade MD](https://www.tomwademd.net/wp-content/uploads/2017/12/fig1-5.png)
2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 11 of 11 - Tom Wade MD
![Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study - Frontiers Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study - Frontiers](https://www.frontiersin.org/files/MyHome%20Article%20Library/851295/851295_Thumb_400.jpg)
Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study - Frontiers
![Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease](https://www.frontiersin.org/files/Articles/897936/fmed-09-897936-HTML-r1/image_m/fmed-09-897936-g001.jpg)
Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
![Cureus | Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options? Cureus | Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options?](https://assets.cureus.com/uploads/figure/file/286749/b8b7ea60463311ecb976955336d4f7bc-Figure-1.png)
Cureus | Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options?
![Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev - Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev -](https://almclinmed.ru/files/journals/1/articles/1619/supp/1619-7803-1-SP.jpg)
Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev -
![Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev - Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev -](https://almclinmed.ru/public/journals/1/cover_issue_66_en_US.jpg)
Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study - Knyazev -
![Frontiers | Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence Frontiers | Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence](https://www.frontiersin.org/files/MyHome%20Article%20Library/708310/708310_Thumb_400.jpg)